Devyser Diagnostics AB has secured a CFTR NGS proposal with UNC Hospitals. The proposal with UNC Hospitals is valid for a period of up to four years. Indicative order value is estimated to be approximately SEK 2.5 million annually.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
112 SEK | +2.75% | +0.90% | +42.49% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+42.49% | 175M | |
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |
- Stock Market
- Equities
- DVYSR Stock
- News Devyser Diagnostics AB
- Devyser Diagnostics AB Achieves Breakthrough in the US with Cystic Fibrosis NGS Test